诺和锐30对早期糖尿病肾病血糖波动的影响

接受诺和灵30R治疗的早期2型糖尿病肾病患者（HbA1c〉7.5%）30例改为诺和锐30治疗12周,结果：BMI、FBG、24h平均血糖水平（24hMBG）无明显变化,2hPG、ACR均明显下降（P均〈0.05）,HbA1c有所下降,但差异无统计学意义（P〉0.05）;日间平均血糖波动幅度（MAGE）、日间血糖平均绝对差（MODD）及餐后血糖波动幅度（PPGE）,均有不同程度的下降（P均〈0.05）。结论：诺和锐30可减轻早期糖尿病肾病患者血糖波动,降低尿微量白蛋白排泄率。

Effects of biphasic insulin aspart 30/70 on blood glucose variability in early diabetic nephropathy

Objective To explore the effects of biphasic insulin aspart 30/70（ BIAsp 30） on blood glucose variability in type 2 diabetic patients with incipient nephropathy. Methods Thirty type 2 diabetic patients with incipient nephropathy（HbAlc 〉 7.5% ） previously treated with Premixed human insulin 30/70（ BHI 30） were switched to BIAsp 30 for 12 -week treatment. Data from continuous glucose monitor for 72 hours, body mass index （ BMI）, fasting blood glucose （ FBG）, 2 - hour postprandial blood glucose （2hPG）, HbAlc, urine microalbumin （ MA）, and urine creatinine （UCr） were measured. Results After treatment for 12 weeks, no difference in BMI, FBG and 24h - mean blood glucose （24hMBG） were observed （P 〉 0.05 ）. The 2hPG, urinary albumin- to- creatinine ratio（ACR） were decreased significantly （P 〈 0. 05 ）, while the concentration of HbAlc was also lower, but the difference was not statistically significant after the therapy（P 〉0. 05）. There were significantly lower levels of mean amplitude of glycemic excursions （MAGE）, absolute means of daily differences （MODD） and postprandial glucose excursion （PPGE） after treatment than those before treatment. Conclusions The BIAsp 30 treatment could reduce blood glucose variability and microalbuminuria in early diabetic nephropathy.